CTLA4 and melanoma: Our results also demonstrated that high expression levels of MXD3 were associated with worse programmed death 1 protein (PD1) outcomes in glioblastoma (ICB_Zhao2019_PD1), in kidney renal clear cell carcinoma (ICB_Miao2018_ICB), PD1 in melanoma (ICB_Riaz2017_PD1), CTLA4 in melanoma (ICB_Nathanson2017_CTLA4), and ACT in melanoma (ICB_Lauss2017_ACT) but achieved good PD-ligand 1 (LI) therapeutic outcomes in bladder (ICB_Mariathasan2018_PDL1) cancer cohorts.